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Abstract
Purpose: Melanoma at the choroid region is the most common primary cancer that affects the eye in adult patients. Concave
ophthalmic applicators with 106Ru/106Rh beta sources are the more used for treatment of these eye lesions, mainly lesions with
small and medium dimensions. The available treatment planning system for 106Ru applicators is based on dose distributions on a
homogeneous water sphere eye model, resulting in a lack of data in the literature of dose distributions in the eye radiosensitive
structures, information that may be crucial to improve the treatment planning process, aiming the maintenance of visual acuity.
Methods: The Monte Carlo code MCNPX was used to calculate the dose distribution in a complete mathematical model of the
human eye containing a choroid melanoma; considering the eye actual dimensions and its various component structures, due to
an ophthalmic brachytherapy treatment, using 106Ru/106Rh beta-ray sources. Two possibilities were analyzed; a simple water eye
and a heterogeneous eye considering all its structures. Two concave applicators, CCA and CCB manufactured by BEBIG and a
complete mathematical model of the human eye were modeled using the MCNPX code. Results and Conclusion: For both eye
models, namely water model and heterogeneous model, mean dose values simulated for the same eye regions are, in general,
very similar, excepting for regions very distant from the applicator, where mean dose values are very low, uncertainties are
higher and relative differences may reach 20.4%. For the tumor base and the eye structures closest to the applicator, such as
sclera, choroid and retina, the maximum difference observed was 4%, presenting the heterogeneous model higher mean dose
values. For the other eye regions, the higher doses were obtained when the homogeneous water eye model is taken into consid-
eration. Mean dose distributions determined for the homogeneous water eye model are similar to those obtained for the heter-
ogeneous eye model, indicating that the homogeneous water eye model is a reasonable one. The determined isodose curves give
a good visualization of dose distributions inside the eye structures, pointing out their most exposed volume.
Keywords: Eye Brachytherapy; Monte Carlo; Dose Distribution; Ruthenium-106
Introduction
Beta radiation is the name given to energetic electrons emit-
ted by the nucleus of unstable isotopes. Because of its physi-
cal characteristics, such as short range, resulting in large dose
fall-off with distance and lower doses to the neighboring
healthy tissues; beta radiation is largely used in brachy-
therapy applications as radiation sources for treatment of
small lesions of the eye.1
90Sr/90Y and 106Ru/106Rh are the more used beta sources for
the treatment of superficial tumors. Only 106Ru/106Rh appli-
cators remain commercially available. They are used as con-
cave applicators. The efficacy of such treatments, side effects
and visual acuity long-term results are available in the liter-
ature.1,2,3,4,5,7,8,9,10,11 Studies about conservation of eyesight
after 106Ru brachytherapy of choroidal melanoma show that
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70% of patients with a tumor thickness not exceeding
3.0 mm had visual acuity of 20/40 or better in 5 years.8
Melanoma at the uvea region is the most common primary
cancer that affects the eye in adult patients and its annual
incidence is, approximately, six cases per one million peo-
ple.11 The use of enucleation decreased substantially during
the last decades by the emergence of more conservative op-
tions, including brachytherapy with applicators, radiation
treatment with charged particles, transpupillary thermo-
therapy, stereotactic radiosurgery and local resection.12,13
Moore 14 was the first that used radon seed brachytherapy to
preserve the vision for a monocular patient with uveal mel-
anoma. Lommatzsch 4 pioneered the use of β-particles from
106Ru/106Rh and found that, as expected, “the severity and
extension of post-radiation retinopathy is less than after
60Co”.
The usually recommended prescribed radiation dose to uveal
melanoma control is between 80 to 100 Gy, specified at the
tumor apex, depending on its size and location. The treat-
ment period varies from two to fourteen days, depending on
the source`s activity.2,8,10 The choice of both the applicator
model and the most adequate radionuclide for each treat-
ment depends on a diversity of factors, including the prox-
imity to optic nerve and fovea (center of macula), tumor
shape, patient age during treatment and, mainly, height of
the tumor apex.8,9,10 Thus, the treatment plan, applicator
model and radionuclide choice must optimize the dose dis-
tribution to minimize the treatment morbidity.15
According to the ICRU 72 and Collaborative Ocular Mela-
noma Study 1,16,17, the tumor thickness is defined as being the
distance from the inner surface of the sclera to the apex of
the tumor, the sclera is assumed to be 1mm thick. Tumors
are classified as small if they are <3 mm in thickness and <10
mm in diameter; as medium-sized if they are 3- 5 mm in
thickness and 10-15 mm in diameter and as large, if its di-
mensions are >5 mm in thickness and >15 mm in diameter.
Large sizes tumors are usually treated by ophthalmic appli-
cators emitting gamma-rays (either 103Pd or 125I).18,19,20 For
average and small sizes tumors, beta-ray applicators (106Ru or
90Sr) are preferred.2,9,21
The available treatment planning system for 106Ru applicators
is based on simplified physical models of radiation transport
and on a very rough approximation of the anatomy of the
eye, which is assumed to be a homogeneous water sphere.22
The Monte Carlo method has been used widely in dosimetric
research of the human eye with different radioisotopes
(ophthalmic applicators), beta and gamma emit-
ters.23,24,25,26,27,28,29 This method is generally accepted as the
most accurate approach for simulation of absorbed dose dis-
tributions, mainly in the presence of small radiation fields,
like the ones used for eye irradiation.29 However, the deter-
mination of dose distribution produced by 106Ru beta appli-
cators in eye is still a challenge and needs further improve-
ments. Despite the existence of many publications, all of
them are based on the same simplified homogeneous geome-
try of the eye described above. However, the human eye has
different regions and materials and some of them with high
radiation sensitivity, such as the lens and macula.25 Thus, a
complete eye model considering all present regions and their
elemental compositions are required in order to carry out a
more accurate dosimetric study.
Quantify the absorbed radiation dose accurately due to be-
ta-rays near the surface of the ophthalmic applicators is not
an easy task. In fact, it is signiﬁcantly more complex when
different regions and materials that compose the human eye
are considered.
This paper proposes to calculate the dose distribution in a
complete mathematical model of the human eye, using geo-
metrical volumes, containing a choroid melanoma, consid-
ering the eye actual dimensions and its various component
structures such as sclera, choroid, retina, vitreous humor,
cornea, anterior chamber, lens, optic nerve, optic disc, mac-
ula, fovea and foveola. In order to simulate a real adult hu-
man eye, the elemental compositions and densities of the
different parts of the eye as well as the tumor region located
in choroid (choroidal melanoma) were considered.1 The ra-
dioactive element considered for simulation was a
106Ru/106Rh beta emitter brachytherapy source, which is used
as applicators.
Methods and Materials
Radionuclide 106Ru/106Rh
The 106Ru is a β- emitter with maximum energy of E =
39.4 keV, with a half-life of T1/2 = 368.2 d. It decays to 106Rh
with T1/2 = 29.80s, before decaying to 106Pd (stable) with a
maximum beta energy of 3.54 MeV.1 The radiation relevant
to radiotherapy is the beta radiation of the radionuclide
106Rh. The gamma radiation contributes only negligibly, 1%
to the total dose in the target volume and therefore does not
need to be taken into account.15 The 106Rh beta spectrum
used in the simulations was taken from ICRU Report 72.1
Monte Carlo code-MCNPX
The Monte Carlo method is based on probabilistic concepts
resulting from the interactions of individual particles (elec-
trons, in the present study) migrating within complex geom-
etries and various kinds of materials.30 The method is applied
in order to simulate random and individual trajectories
through the medium taking into account physical parameters
such as density, chemical composition of the materials, par-
ticles that will be simulated, and characteristics of the
source. Monte Carlo code MCNPX comprehends a wide
range of atomic numbers and materials 30, such as e.g. Ag and
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soft tissue, which were used to model the applicators and eye
geometry studied in the present work.
All inputs were modeled using the Monte Carlo code
(MCNPX) version 2.5.0.30 The *F8 tally (MeV) was used to
score the energy deposited in each structure of interest. The
simulations were carried out considering the transport of
electrons until the relative error converge to levels below 5%
thus ensuring reliable results according to the limits of relia-
bility presented in the guide interpretation relative error on
MCNP.31
Geometric shape, dimensions and mathematical mod-
eling of the 106Ru/106Rh applicators
The 106Ru/106Rh applicators simulated in this work are con-
cave CCA and CCB types, produced by the BEBIG Eckert &
Ziegler BEBIG GmbH.15 These applicators models are the
most commonly used for the treatment of uveal and cho-
roidal melanomas of small and medium sizes.1,27,29 Their ge-
ometric parameters and radiation activities are presented in
Table 1.
The mathematical model of the applicators was defined as
three concentric spherical shells of 24 mm internal diameter.
The pure silver inner spherical shell has a thickness of
0.1 mm (silver window), this window stop all the
low-energy (Emax = 39 keV) beta particles from 106Ru source.
The next spherical shell presents a silver thickness of 0.2 mm
with a 0.1 μm thickness layer of the radioisotope (106Rh)
electrolytically deposited on the concave surface. The outer
spherical layer, the base of the applicator (silver support), has
a thickness of 0.7 mm. These three spherical shells were cut
by two cones with an aperture of α = arcsine (R/Rc), where R
and Rc are the internal radius of the applicator and the cur-
vature radius of the inner surface, respectively. The geome-
try of the applicator is presented in Figure 1. In this work,
the source was assumed to have a uniform distribution of the
radioactive material over its active area.
Dosimetric characteristics of 106Ru/106Rh eye applica-
tors
According to the manufacturer manual, the radiation ab-
sorbed dose rate in water due to the 106Ru/106Rh applicators
was measured with a plastic scintillation detector having
high spatial resolution. Its calibration is based on the NIST
(National Institute of Standards and Technology, USA) pri-
mary standard for radiation absorbed dose to water for beta
radiation sources.15
TABLE 1: Geometric parameters and activities of the 106Ru/106Rh eye applicators15
FIG. 1: Mathematical model scheme of the 106Ru/106Rh applicators.
The expanded measured uncertainty of the dose values pro-
vided by the manufacturer is ±20% (95% confidence level).
The calibration data of the depth dose rate distribution (11
measurement points along the applicator symmetry axis,
Type Diameter
(D) (mm)
Active Diameter
(Da) (mm)
Height
(h) (mm)
Radius of curvature
(Rc) (mm)
Nominal activity
CCA 15.3 13.0 3.3 12 10.0 MBq
CCB 20.2 17.8 5.4 12 19.0 MBq
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from 0 to 10 mm) and the relative dose rate distribution at a
1 mm distance from the applicator surface (33 measurement
points) are presented in the source calibration certificate.
According to the source manufacturer data, these applicators
were produced with a nominal reference dose rate of
80 mGy/min at a source-measurement point distance of
2 mm on the applicator symmetry axis. This value is equiva-
lent to a surface dose rate of approximately 120 mGy/min.
Applicators production-related deviations from nominal
values ranging from -10% to +60% are possible.15
Aiming the validation of the Monte Carlo simulations car-
ried out in the present work, percent depth dose curves
(PDD), dose lateral profiles and isodoses curves in water
were determined and compared to the results obtained using
the data from the manufacturer manual and source certifi-
cate, as well as to the data presented by Hermida-López.37
In this study, aiming the calculation of radiation dose distri-
butions in water, percent depth dose curves (PDD), dose
lateral profiles and isodoses curves were determined. It was
constructed a grid composed of 2.432 bins of
0.15 × 0.15 × 0.15 mm3. The grid ranged from -13.30 to
13.30 mm in the lateral axis and from 1.85 to 13.05 mm in
depth axis, sweeping, inclusively, the outer area of the ap-
plicator. This grid was placed on the depth axis of the appli-
cator that was attached to a water sphere, representing the
eyeball.
In order to calculate the relative dose distributions in depth
and laterally, considering each applicator, eleven positions of
dose evaluation were marked at the grid, in intervals of
1 mm along the axis of symmetry of the applicator, from the
applicator’s inner surface. The lateral dose distributions were
determined for six depths, 1, 2, 3, 4, 6, and 8 mm, in lateral
intervals of 1 mm. The relative doses have been normalized
to 100% at a depth of 2 mm.
Eye anatomy and mathematical model of the eye and
tumor
The adult human eye has, in average, 24.0 mm in diame-
ter.1,20,35 The outer coat consists of the opaque sclera, with a
thickness of 0.3 - 1.0 mm and a diameter of 24.0 mm. The
uvea (middle coat) is formed by the choroid (thickness of
0.1- 0.3 mm), the ciliary body (mid-zonal portion, thickness
of 2.0 mm) and the iris (anterior portion, thickness of 0.5-
3.0 mm), which represents the origin of different types of
uveal melanoma.
The inner coat consists of the retina, including the retinal
pigment epithelium (thickness 0.1 mm). The vitreous humor,
filling the inner part of the globe, does not contain any vital
cells. It is composed of 99% of water. The optic nerve enters
the globe at the optic disc (papilla of the optic nerve). The
macula (4.0 mm diameter) represents anatomically the cen-
tral portion of the retina with the highest concentration of
visual cells and is therefore the most important structure for
the visual acuity. The lens, which have a density of
1.07 g/cm3, separate the vitreous from the anterior chamber
filled with aqueous humor.1 Figure 2 shows the anatomy of
the eye.
FIG. 2: The human eye diagram (COMS).
In the eye mathematical model considered, using as refer-
ence the dimensions of the eye model presented in AAPM
and ABS Task Group 129 Report 20, the eye globe has been
deﬁned as four concentric spherical shells centered at the
origin of the coordinates system (Figure 3). This anatomy is
composed of three layers including the eye body, namely the
sclera (outer) with diameter of 24.0 mm and thickness of
1.0 mm, choroid (middle) with diameter of 23.0 mm and
thickness of 0.3 mm, retina (inner) with 22.0 mm diameter
and thickness of 0.1 mm. The vitreous humor is the spherical
region limited by the inner surface of the retina.
The tumor region has been defined as an ellipsoid, cut by the
spherical surface of choroid, forming a semi-ellipsoid,
dome-shaped, situated inside the eye. The tumor spreads in
the interior of the retina and vitreous humor, with a thick-
ness of 4.0 mm and a basal diameter of 13.0 mm (Figure 3).
The cornea was modeled as an elliptical shell limited by two
concentric ellipses, situated at the outer surface of the cho-
roid with a thickness of 0.5 mm. The optic nerve and its wall
are represented, by a cylinder and a cylindrical shell, respec-
tively, concentrically localized. Both extend from the outer
sclera surface, rotated by 20˚ in relation to the coordinate
system (Figure 3).
The lens was represented as an ellipsoid having its center
localized 8.0 mm from the coordinate system center. The
anterior chamber is the geometric region between the sur-
face that defines the cornea inner wall and the outer surface
of the vitreous humor (Figure 3).
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The macula is a disk-like structure with 4.0 mm in diameter
situated within the retina. The fovea is a depression in the
center of the macula, having a structure disk-like of 1.5 mm
in diameter. In its center there is a depression of about
0.35 mm in diameter, designated by foveola. The optic disc
(papilla) is the part of the optic nerve that protrudes into the
back of the eye; being a slightly oval structure with 1.8 mm
in diameter, located in both the sclera and retina (Figure 3).
Materials, elemental composition and density of each eye
component are shown in Table 2. For comparison, the eye
regions were also simulated considering that they were
composed only by water, with density of 1.0 g/cm3.
The *F8 tally of MCNPX provides the energy deposited in a
cell, in MeV. In order to convert the results of the *F8 tally
in mGy/min, that is, absorbed dose rate in tissue, the results
from *F8 tally were divided by the mass (g) of each eye ana-
tomical structure (cell), including the tumor, multiplied by
the unit conversion factor (9.61x10-3 J.kg-1.min-1), consider-
ing 1 MBq as the source activity. For different activity values
in MBq, the results should be multiplied by these values,
equation (1). Ḋ = ∗ A            (1),
Where Ḋ is the dose rate in mGy/min, *F8 is a MCNPX tally
command that provides the deposited energy in MeV, A is
the source activity in Bq and M is the mass in g.
All inputs were simulated for a total of 2x108 electron histo-
ries, resulting in statistical uncertainties generated by *F8
tally lower than 1%.
TABLE 2: Density and elemental composition of each eye region.35,36
Sclera, choroid, Retina,
Cornea, Optic nerve and
Wall, Macula, Optic disc,
Fovea, Foveola and Tumor.
Soft tissue: (1.04 g/cm3)
Percent
by weight
Lens
(1.07 g/cm3)
Percent
by weight
Vitreous body
and anterior
chamber
Water:(1g/cm3)
Percent
by
weight
H 10.454 H 9.6 H 0.112
C 22.663 C 19.5 O 0.888
N 2.490 N 5.7 - -
O 63.525 O 64.6 - -
Na 0.112 Na 0.1 - -
Mg 0.013 P 0.1 - -
Si 0.030 S 0.3 - -
P 0.134 Cl 0.1 - -
S 0.204 - - - -
Cl 0.133 - - - -
K 0.208 - - - -
Ca 0.024 - - - -
Fe 0.005 - - - -
Zn 0.003 - - - -
Rb 0.001 - - - -
Zr 0.001 - - - -
FIG. 3: Coronal view of the simulated eye and tumor, 2D.
Results
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Relative Depth Dose and Lateral Dose Distributions Using MCNPX
Relative depth dose and lateral dose profiles were tallied along the symmetry axes of the applicators, extending from the inner
concave surface into the water sphere. The Figures 4, 5 and 6 show the relative depth dose and lateral profile dose distributions
along distances perpendicular to the symmetry axis at different depths, simulated with MCNPX *F8 tally, for both CCA and
CCB applicators compared with experimental data provided by the manufacturer, BEBIG, and with the MC-PENELOPE
calculations carried out by Hermida-López 37, whose results were well discussed and compared with those of other authors.32,33,34
FIG. 4: Central axis depth dose curves for CCA applicator: Comparison between BEBIG GmbH manufacturer manual data and MCNPX (present
work) results (left Figure). Comparison between PENELOPE/Hermida-López 37 simulations and MCNPX (present work) results (right Figure).
The relative doses have been normalized to 100% at a depth of 2 mm (left figure) and 100% at a depth of 1 mm at the central axis (right Figure).
FIG. 5: Central axis depth dose curves for CCB applicator: Comparison between BEBIG GmbH manufacturer certificate data and MCNPX
(present work) results (left Figure). Comparison between PENELOPE/Hermida-López 37 simulations and MCNPX (present work) results (right
Figure). The relative doses have been normalized to 100% at a depth of 2 mm (left Figure) and 100% at a depth of 1 mm at the central axis (right
Figure).
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FIG. 6: Lateral dose distributions calculated using MCNPX at 1, 2, 3, 4, 6, and 8 mm depths for CCA (left figure) and CCB (right figure)
applicators. The data are compared to PENELOPE/Hermida-López 37 results. The relative doses have been normalized to 100% at a depth of 1
mm at the central axis.
Figures 4 and 5 show a good agreement between the results
obtained in this work and the data using the
manufacturer-BEBIG certificate and manual15 and simulated
by Hermida-Lopéz 37 (within the statistical uncertainty, 20%
for data obtained using the manufacturer manual and 1% for
both Monte Carlo procedures, present work and obtained by
Hermida-López)37. The largest differences were found at
depths 4 e 5 mm. For example, for CCB applicator, at 4 mm
depth, the relative dose obtained by Hermida-López is 44%,
while, in the present work, the relative dose value found is
43%. For CCA applicator, at 5 mm depth, the relative dose
calculated by Hermida-López is 25.8% and the value
determined in this work is 26.8%. These results validate the
MCNPX Monte Carlo Code used in the present work.
However, comparing MCNPX results with manufacturer
data, some larger discrepancies were found. For example, at
the surface of CCB applicator, a difference of 6 % was
determined and for CCA applicator, at depths 9 and 10 mm,
a difference of 8% was found. One should have in mind that
manufacturer data uncertainties are about 20 %, a value
higher than those found to percent differences between
manufacturer data and MCNPX results. Other authors had
already found similar differences comparing Monte Carlo
data and manufacturer data.27,32,33
Assuming the nominal activity values presented in Table 1,
dose rates in the center of the surface of applicators CCA and
CCB were, respectively, 96.4 and 129.1 mGy/mim. Using the
calibration certificate of the CCB-1853 applicator, it was
determined a dose rate of 128.3 mGy/min (dose rate
corrected by source decay in 2013) in the center of the
applicator surface, indicating a good agreement between
Monte Carlo and certificate values. This comparison
couldn´t be done for CCA applicator because its certificate
wasn´t available.
Dose distribution in the eye
The MCNPX *F8 tally was used to quantify the energy
deposition in the choroidal melanoma and all eye structures
regions.
Table 3 shows the dose rates to the tumor apex and the
tumor base, as well as the mean doses rate values in all
structures at risk of the eye, such as sclera, choroid, retina,
vitreous humor, optic nerve, optic nerve wall, cornea,
anterior chamber, optic disc, lens, macula, fovea and foveola;
calculated by simulating ophthalmic applicators of
106Ru/106Rh, CCA and CCB models, attached to the human
eye model considered in this work.
For comparison, were considered two eye models, namely
one composed by real heterogeneities of the eye and another
entirely composed of water.
Observing Table 3, considering the two types of applicators,
it is possible to find that, for both eye models, namely water
model and heterogeneity model, mean dose values calculated
for the same structures are, in general, very similar,
excepting for structures very distant from the applicator,
where dose values are very low, uncertainties are higher and
relative differences may reach 20.4 %. For the tumor base
and the eye structures closest to the applicator such as sclera,
choroid and retina, the most important structures for the
treatment considered, the maximum difference observed was
4 %. For these structures, higher mean dose values are found
when the heterogeneous model is considered. For the other
eye structures, the higher mean doses are determined when
the homogeneous water eye model is taken into
consideration.
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TABLE 3: Dose rate, ̇ (mGy/min), obtained by simulation with MCNPX, at the structural regions of the eye, considering a water eye model
and an eye model with actual heterogeneities.
Plaque CCB
Dose Rate [mGy/(min MBq)]
Plaque CCA
Dose Rate [mGy/(min MBq)]
Eye structures Mass(g) Heterogeneous
eye model
Water eye
model
Relative
difference(%)
Heterogeneous
eye model
Water eye
model
Relative
difference(%)
Tumor-apex 0.277 36.81 38.27 -3.4 22.80 23.98 -3.5
Tumor-base
(inner sclera)
99.50 95.67 3.8 71.27 68.52 3.9
Lens 0.15 1.04 1.06 -1.9 0.160 0.165 -2.9
Anterior chamber 0.185 0.67 0.69 -3.0 0.083 0.087 -4.8
Cornea 0.177 0.35 0.36 -2.8 0.045 0.046 -2.2
Vitreos humor 4.53 6.26 6.40 -2.3 1.80 1.86 -3.3
Retina 0.149 7.55 7.43 1.6 1.33 1.31 1.5
Choroid 0.461 7.60 7.50 1.3 1.23 1.22 0.8
Sclera 1.730 18.72 18.32 2.1 7.28 7.12 2.2
Optic nerve (ON) 0.269 7.84E-03 7.81E-03 3.8 2.70E-03 2.69E-03 0.37
Optic nerve wall 0.086 9.30E-03 8.50E-03 8.6 2.74E-03 2.67E-03 2.6
Macula 1.76E-03 1.46E-02 1.56E-02 -6.7 1.58E-02 1.60E-02 -1.27
Optic disc 2.18E-03 1.20E-02 1.30E-02 -8.0 2.70E-03 2.80E-03 -3.70
Fovea 8.43E-04 3.82E-02 4.60E-02 -20.4 2.64E-03 3.16E-03 -19.7
Foveola 2.32E-05 4.09E-02 4.10E-02 -0.4 7.22E-02 7.30E-02 -1.1
FIG. 7: Relative isodose distributions due to CCA and CCB applicators. The relative doses have been normalized to 100% at a depth of 2 mm.
Figures (a) and (b) present the dose distributions in water, disregarding the eye presence. Figures (c) and (d) present dose distributions due to
the same applicators inside the water eye model.
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Considering that dose rate values provided by the applicators
manufacturer calibration certificate present an uncertainty
about 20 %, to consider the homogeneous water eye model
for mean dose distribution simulation aiming treatment
planning is reasonable.
The mean dose rate values presented in Table 3 can give a
rough idea about dose distribution in the eye, as whole,
indicating the high dose gradient presented by 106Ru/106Rh
beta source. However, in radiotherapy it is important to
know the volumetric dose distribution for each important
structure. For the applicator/eye geometry considered in the
present work, dependent of the tumor position, one can find
that mean dose values don´t describe properly the dose
distribution in the sclera, choroid and retina. Considering
Figure 7, which presents the isodoses distribution in the eye,
it is possible to observe, for example, that higher dose values
are concentrate at the upper part of the eye lens, being a
mean dose value not representative of volumetric dose
distribution inside the structure. The lower part of the
structure practically is exposed to very low doses. In the
cases of sclera, choroid and retina, the isodose curves give a
good visualization of the parts of these structures more
exposed to the radiation treatment. Naturally, the present
discussion is valid for the special applicator position
considered. For other tumor positions, consequently other
applicator localization, new analysis are requested and
different structures may receive higher doses. Obviously,
sclera, choroid and retina will always be exposed to high
doses.
Figures 7 (a) and (b) display the isodose distributions
simulated for the CCB and CCA applicators in water, along
applicator axis as a function of the transverse distance.
The isodose plots highlight the differences between the dose
profiles produced by both applicators. The dose distribution
for CCA applicator decreases uniformly along the applicator
symmetry axis and a large lateral dose fall-off is observed,
while the CCB applicator lateral dose distribution fall-off
doesn’t decrease so rapidly. This difference can be, mainly,
due to the different extensions of the active regions in both
applicators.
The goal of a radiation treatment is to minimize doses to
healthy tissues with recommended maximum dose to the
tumor. Therefore, the doses to the critical structures are
crucial for the risk of side effects, especially for maintaining
visual acuity. Uncertainty in the tumor location is another
critical factor. The risk of local recurrence increases for
tumors close to the optic disc or fovea/macula.38 Considering
the wealth of detail with which the eye model was
constructed in this work, it is possible to estimate the dose
for any of these structures, with the flexibility to vary the
tumor dimensions and locations, applicator position and thus
verify the doses in critical structures near the tumor.
Once dose rates fall-off rapidly in the more distant structures
from the applicator, due to the limited range of the electrons
in tissue, there is a limitation of tumors size that are able to
be reasonably treated with such applicators; justifying the
important therapeutic indication of the 106Ru/106Rh
applicators for small and medium tumors.3,5,7,8,9
Discussion and Conclusions
The simulated results obtained with the use of MCNPX
Monte Carlo code for mean doses rates distributions in a
complete mathematical model of the human eye for two
106Ru/Rh106 applicators, CCA and CCB, show that the correct
choice of the applicator model, the knowledge of the
thickness and tumor localization and the prescription dose
are fundamental in order to provide an effective treatment.
Mean dose rate distributions were simulated in two eye
models composed only by water and considering eye
heterogeneities. For the tumor base and the eye structures
closest to the applicator such as sclera, choroid and retina,
the most important structures for the treatment considered,
the maximum difference observed was 4 %. For these
structures, higher dose values are found when the
heterogeneous model is considered. For the other eye
structures, the higher doses are determined when the
homogeneous water eye model is taken into consideration.
Applicators models CCA and CCB are the most used for
treatments of choroidal melanomas of small size; however,
published experimental data for these applicators are scarce,
owing to the difficulties entailed in measuring small
irradiated fields. The simulated 106Ru/Rh106 applicators seem
to be effective for the treatment concerned. Because of the
106Ru/Rh106 applicators dosimetric characteristics, some care
must be taken to ensure adequate coverage of the tumor
volume. Choroidal and uveal melanomas are relatively
resistant to irradiation; thus, the brachytherapy doses needed
to control these tumors are associated with a substantial risk
of radiation damage in the critical structures. Larger tumors
(>5mm) and more anterior ones are more likely to develop
complication after brachytherapy treatment, once these
parameters affect the radiation dose to the lens, optic disc
and macula/fovea.
In present work, considering the chosen tumor i.e. its
localization region, thickness and volume, the CCA
applicator presented better results, namely the dose
delivered to critical structures were lower. However, the
important point is to know the behavior of isodoses
generated by both applicators in order to decide the
appropriate one to be used according to the tumor to treated,
its localization and dimensions. Without knowing the
scenario to be considered, it isn’t possible to elect the best
plaque to be applied.
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The use of the treatment planning system together with
Monte Carlo simulations would be the best procedure for
ophthalmic brachytherapy planning. However, this is a pro-
cedure difficult to be followed in common radiotherapy
centers. In many ophthalmic brachytherapy centers, mainly
localized in underdeveloped and developing countries, no
treatment planning for ophtalmologic brachytherapy is car-
ried out. Treatment doses are determined using doses values
obtained from the source calibration certificate, corrected for
the source radioactive decay. Therefore, the eye model de-
veloped in this work and the doses distribution determined
in the present investigation are of high importance to give to
the physician an idea of dose distributions involved in the
treatment. Additionally, the method permits calculations for
additional tumor localizations, aiming the calculation of
doses.
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